SanuWave provides non-invasive surgical solutions for orthopedic conditions, such as chronic plantar fasciitis and chronic lateral epicondylitis, more commonly known as heel pain and tennis elbow. Its product, the OssaTron, is one of the first extracorporeal shockwave systems approved by the U.S. Food and Drug Administration for the treatment of multiple orthopaedic conditions, which have failed to respond to conservative treatment. The use of shock wave technology to treat these conditions represents a non-invasive breakthrough. SanuWave maintains its headquarters in Marietta, Ga. SanuWave is a privately held company, and it employs approximately 80 people.
Partial Data by Infogroup (c) 2025. All rights reserved.